Can nitrofurantoin be safely prescribed for an uncomplicated lower urinary‑tract infection in a pregnant adult who is not at term (≥38 weeks), has no G6PD deficiency, and has adequate renal function?

Nitrofurantoin in Pregnancy (Not at Term)

Yes, nitrofurantoin can be safely prescribed for uncomplicated lower urinary tract infections in pregnant women who are not at term (≥38 weeks), have no G6PD deficiency, and have adequate renal function. 1

Evidence-Based Recommendation

The 2024 European Association of Urology guidelines explicitly list nitrofurantoin as a first-line treatment option for uncomplicated cystitis in women, with specific dosing regimens provided 1:

• Nitrofurantoin macrocrystals: 50-100 mg four times daily for 5 days
• Nitrofurantoin monohydrate or macrocrystals: 100 mg twice daily for 5 days
• Nitrofurantoin macrocrystals prolonged release: 100 mg twice daily for 5 days

The 2024 JAMA Network Open guidelines similarly recommend nitrofurantoin as a reasonable drug of choice for uncomplicated cystitis, emphasizing its robust evidence of efficacy and ability to spare more systemically active agents 2.

Safety Profile in Pregnancy

First and Second Trimester Safety

The evidence strongly supports nitrofurantoin use during early and mid-pregnancy:

• A large population-based cohort study of 105,492 pregnancies (including 1,329 first-trimester exposures) found no association between nitrofurantoin and major congenital malformations (adjusted OR = 0.85,95% CI 0.67-1.08) 3

• A retrospective analysis of 91 pregnancies treated with nitrofurantoin showed no drug-related abnormal events, with outcomes comparable to the general U.S. population 4

• The American College of Obstetricians and Gynecologists (ACOG) Committee Opinion states that nitrofurantoin may be used as a first-line agent during the second and third trimesters, and is still appropriate in the first trimester when no suitable alternatives exist 5

Critical Contraindications

Absolute contraindications:

• At term (≥38 weeks gestation): Risk of hemolytic anemia in the newborn 6
• G6PD deficiency: Risk of oxidant-induced hemolytic anemia 6, 7
• Renal impairment (creatinine clearance <60 mL/min): Increased risk of peripheral neuropathy and reduced drug efficacy 6

Clinical Algorithm for Use

Step 1: Confirm gestational age

• If <38 weeks → proceed to Step 2
• If ≥38 weeks → DO NOT USE nitrofurantoin; choose alternative (e.g., cephalosporin, fosfomycin)

Step 2: Assess renal function

• If CrCl ≥60 mL/min → proceed to Step 3
• If CrCl <60 mL/min → DO NOT USE nitrofurantoin

Step 3: Screen for G6PD deficiency (if patient ethnicity suggests risk: African, Mediterranean, Asian descent)

• If G6PD normal or deficiency excluded → SAFE TO USE
• If G6PD deficient → DO NOT USE nitrofurantoin

Step 4: Prescribe appropriate regimen

• Standard: 100 mg twice daily for 5 days 1
• Ensure patient understands to complete full course

Important Caveats

Trimester-specific considerations:

• The EAU guidelines note that trimethoprim should not be used in the first trimester and trimethoprim-sulfamethoxazole should not be used in the last trimester 1, making nitrofurantoin particularly valuable as a first-line option throughout most of pregnancy

Monitoring:

• Pregnant women with UTI should have urine culture performed (unlike non-pregnant women with uncomplicated cystitis) 1
• If symptoms don't resolve or recur within 4 weeks, repeat culture and susceptibility testing 1

Risk-benefit in first trimester:

• While evidence is reassuring, ACOG emphasizes that untreated UTIs commonly lead to serious maternal and fetal complications, making treatment imperative even if theoretical concerns exist 5

The evidence base demonstrates that nitrofurantoin is both effective and safe when used appropriately in pregnancy, with the critical exception of use at term.